Smith Anglin Financial’s Pfizer PFE Stock Holding History

Smith Anglin Financial’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,000	Closed	-$5K	–	150
2021 Q3	$5K	Buy	+1,000	New	+$44.3K	﹤0.01%	136

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Smith Anglin Financial's PFE Position: Q2 2025 in Review

Smith Anglin Financial sold out of Pfizer (PFE) in Q2 2025, closing a stake of 10,211 shares — an estimated $259K sold.

Smith Anglin Financial first reported a position in PFE in Q4 2020 and held it in 17 quarters. The position peaked at $652K in Q3 2024. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

Smith Anglin Financial reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
Smith Anglin Financial sold 10,211 Pfizer shares in Q2 2025, an estimated $259K.
Smith Anglin Financial first reported a position in Pfizer in Q4 2020 and held it in 17 quarters.
Smith Anglin Financial's Pfizer position peaked at $652K in Q3 2024.
2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Smith Anglin Financial's 13F filing for Q2 2025, filed 17 Jul 2025.